Table 5.

Comparison between tardive dyskinesia at CMHC in 1980s and 2000s.

Comparison	1980sa	2000sb
Proportion on conventional at baseline	100%	23–36%*
Patients at risk	362	352
Patient-years of follow-up	1127	783
Age at baseline, median	41 years	42 years
Sample % African-American	23%	35%
Sample % schizophrenia**	58%	67%
CPZ eq dose at baseline, median	250 mg	300 mg
Lifetime CV exposure at baseline, median	6.1 years	6.0 years
Lifetime AT exposure at baseline, median	0	2.2 years
Tardive dyskinesia prevalence	33%	32%
Tardive dyskinesia incidence	0.053/year	0.066/year
Severity of incident cases***	4.8	4.8

all data except prevalence estimates from the at-risk samples

^aprevalence data 1982–1983 as published ³; at-risk baseline and incidence data 1985–1990 as published ⁴.

^bdata from present study 2000–2005

^*23% conventional alone at baseline in the at-risk sample, 36% including conventional in combination with atypical

^**schizophrenia or schizoaffective disorder

^***mean of average AIMS total scores across four exams contributing to incident case detection